Cargando…

Duration of anti-SARS-CoV-2 antibodies much shorter in India

Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Nishant, Bhartiya, Shibal, Singh, Tarundeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641879/
https://www.ncbi.nlm.nih.gov/pubmed/33189428
http://dx.doi.org/10.1016/j.vaccine.2020.10.094
_version_ 1783606015318556672
author Kumar, Nishant
Bhartiya, Shibal
Singh, Tarundeep
author_facet Kumar, Nishant
Bhartiya, Shibal
Singh, Tarundeep
author_sort Kumar, Nishant
collection PubMed
description Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors and nurses) were more likely to be seropositive. Sixty-two (7.74%) had been previously diagnosed with RT PCR test for SARS-CoV-2. Of these, 44 (71%) were seronegative. Upto 28 days after a positive PCR test, 90% of subjects were found to be seropositive. This reduced to less than half (38.5%) between 29 and 42 days. None of 28 infected HCWs who had the RT-PCR more than 50 days ago tested positive for antibodies. It seems likely that cellular immunity plays a larger role in defence against the illness.
format Online
Article
Text
id pubmed-7641879
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-76418792020-11-05 Duration of anti-SARS-CoV-2 antibodies much shorter in India Kumar, Nishant Bhartiya, Shibal Singh, Tarundeep Vaccine Short Communication Seroprevalence survey, for antibodies to SARS-CoV-2, of healthcare workers (HCW) working in three Government run hospitals in Mumbai was carried out in June 2020. Among the 801 HCWs tested, seroprevalence was 11.1%. Males (13.5% vs. 8.9% in females) and ancillary workers (18.5% vs 6.9% in doctors and nurses) were more likely to be seropositive. Sixty-two (7.74%) had been previously diagnosed with RT PCR test for SARS-CoV-2. Of these, 44 (71%) were seronegative. Upto 28 days after a positive PCR test, 90% of subjects were found to be seropositive. This reduced to less than half (38.5%) between 29 and 42 days. None of 28 infected HCWs who had the RT-PCR more than 50 days ago tested positive for antibodies. It seems likely that cellular immunity plays a larger role in defence against the illness. Elsevier Ltd. 2021-02-05 2020-11-04 /pmc/articles/PMC7641879/ /pubmed/33189428 http://dx.doi.org/10.1016/j.vaccine.2020.10.094 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Kumar, Nishant
Bhartiya, Shibal
Singh, Tarundeep
Duration of anti-SARS-CoV-2 antibodies much shorter in India
title Duration of anti-SARS-CoV-2 antibodies much shorter in India
title_full Duration of anti-SARS-CoV-2 antibodies much shorter in India
title_fullStr Duration of anti-SARS-CoV-2 antibodies much shorter in India
title_full_unstemmed Duration of anti-SARS-CoV-2 antibodies much shorter in India
title_short Duration of anti-SARS-CoV-2 antibodies much shorter in India
title_sort duration of anti-sars-cov-2 antibodies much shorter in india
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641879/
https://www.ncbi.nlm.nih.gov/pubmed/33189428
http://dx.doi.org/10.1016/j.vaccine.2020.10.094
work_keys_str_mv AT kumarnishant durationofantisarscov2antibodiesmuchshorterinindia
AT bhartiyashibal durationofantisarscov2antibodiesmuchshorterinindia
AT singhtarundeep durationofantisarscov2antibodiesmuchshorterinindia